Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia [ID650]

Incremental Analysis – bendamustine suitable population

1. PAS plus committee preferred assumptions

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.85				
Benda	£15,548	5.26	3.33	£7,527	0.66	0.48	£15,672
R-Clb	£20,002	5.08	3.20	£4,454	-0.17	-0.14	Dominated
R-Benda	£25,250	5.51	3.53	£5,248	0.43	0.33	£15,844
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.27	0.20	£[redacted]

Incremental analysis (dominated removed)

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)	Remove?
Clb	£8,020	4.60	2.85					
Benda	£15,548	5.26	3.33	£7,527	0.66	0.48	£15,672	No
R-Benda	£25,250	5.51	3.53	£9,702	0.26	0.20	£49,542	Yes - Extendedly dominated
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.27	0.20	£[redacted]	No

Final simultaneous analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.85				
Benda	£15,548	5.26	3.33	£7,527	0.66	0.48	£15,672
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.53	0.40	£[redacted]

2. PAS plus committee preferred assumptions and new neutropenia costs

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.85				
Benda	£14,857	5.26	3.33	£7,400	0.66	0.48	£15,407
R-Clb	£18,846	5.08	3.20	£3,990	-0.17	-0.14	Dominated
R-Benda	£24,094	5.51	3.53	£5,248	0.43	0.33	£15,844
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.27	0.20	£[redacted]

Incremental analysis (dominated removed)

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)	Remove?
Clb	£7,456	4.60	2.85					
Benda	£14,857	5.26	3.33	£7,400	0.66	0.48	£15,407	No
R-Benda	£24,094	5.51	3.53	£9,238	0.26	0.20	£47,171	Yes - extendedly dominated
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.27	0.20	£[redacted]	No

Final simultaneous analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.85				
Benda	£14,857	5.26	3.33	£7,400	0.66	0.48	£15,407
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.53	0.40	£[redacted]

3. PAS plus committee preferred assumptions with 0.76 PFS of treatment utility and new neutropenia cost

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.88				
Benda	£14,857	5.26	3.41	£7,400	0.66	0.52	£14,108
R-Clb	£18,846	5.08	3.26	£3,990	-0.17	-0.15	Dominated
R-Benda	£24,094	5.51	3.62	£5,248	0.43	0.36	£14,411
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.27	0.22	£[redacted]

Incremental analysis (dominated removed)

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)	Remove?
Clb	£7,456	4.60	2.88					
Benda	£14,857	5.26	3.41	£7,400	0.66	0.52	£14,108	No
R-Benda	£24,094	5.51	3.62	£9,238	0.26	0.21	£43,335	Yes - extendedly dominated
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.27	0.22	£[redacted]	No

Final simultaneous analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.88				
Benda	£14,857	5.26	3.41	£7,400	0.66	0.52	£14,108
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.53	0.44	£[redacted]

4. PAS plus committee preferred assumptions with 0.76 PFS of treatment utility and original neutropenia cost

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)

Clb	£8,020	4.60	2.88				
Benda	£15,548	5.26	3.41	£7,527	0.66	0.52	£14,350
R-Clb	£20,002	5.08	3.26	£4,454	-0.17	-0.15	Dominated
R-Benda	£25,250	5.51	3.62	£5,248	0.43	0.36	£14,411
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.27	0.22	£[redacted]

Incremental analysis (dominated removed)

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)	Remove?
Clb	£8,020	4.60	2.88					
Benda	£15,548	5.26	3.41	£7,527	0.66	0.52	£14,350	No
R-Benda	£25,250	5.51	3.62	£9,702	0.26	0.21	£45,513	Yes - extendedly dominated
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.27	0.22	£[redacted]	No

Final simultaneous analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.88				
Benda	£15,548	5.26	3.41	£7,527	0.66	0.52	£14,350
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.53	0.44	£[redacted]

Incremental Analysis – bendamustine unsuitable population

1. PAS plus committee preferred assumptions

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)

Clb	£8,020	4.60	2.85				
R-Clb	£20,002	5.08	3.20	£11,982	0.48	0.34	£34,736
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.70	0.53	£[redacted]

Final simultaneous incremental cost-effectiveness analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.85				
G-Clb	£[redacted]	5.79	3.73	£[redacted]	1.19	0.88	£[redacted]

2. PAS plus committee preferred assumptions and new neutropenia costs

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.85				
R-Clb	£18,846	5.08	3.20	£11,390	0.48	0.34	£33,021
G-Clb	£[redacted]	5.79	3.73	£[redacted]	0.70	0.53	£[redacted]

Final simultaneous incremental cost-effectiveness analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.85				
G-Clb	£[redacted]	5.79	3.73	£[redacted]	1.19	0.88	£[redacted]

3. PAS plus committee preferred assumptions with 0.76 PFS of treatment utility and new neutropenia cost

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.88				
R-Clb	£18,846	5.08	3.26	£11,390	0.48	0.37	£30,489
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.70	0.59	£[redacted]

Final simultaneous incremental cost-effectiveness analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£7,456	4.60	2.88				
G-Clb	£[redacted]	5.79	3.84	£[redacted]	1.19	0.96	£[redacted]

4. PAS plus committee preferred assumptions with 0.76 PFS of treatment utility and original neutropenia cost

Incremental analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc.QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.88				
R-Clb	£20,002	5.08	3.26	£11,982	0.48	0.37	£32,072
G-Clb	£[redacted]	5.79	3.84	£[redacted]	0.70	0.59	£[redacted]

Final simultaneous incremental cost-effectiveness analysis

Technologies	Total costs (£)	Total LYG	Total QALYs	Inc. costs (£)	Inc. LYG	Inc. QALYs	ICER (£/QALY gained)
Clb	£8,020	4.60	2.88				
G-Clb	£[redacted]	5.79	3.84	£[redacted]	1.19	0.96	£[redacted]